IRCT20240208060941N3 IRCT 2025-03-26 Pak-Emirates Military Hospital Eltrombopag and Platelet Recovery in Patients with Dengue Fever Effect of Eltrombopag Olamine on Platelet Recovery and Bleeding Complications Among Dengue Patients with Severe Thrombocytopenia_ A Randomized Controlled Trial 2024-10-21 anticipated 50 Complete https://irct.ir/trial/79592 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We used simple randomization to ensure an unbiased and equal chance of assignment for all participants. The unit of randomization was the individual participant, ensuring that each subject’s assignment was unaffected by others. The random sequence was generated using a computer-based random number generator (RNG). Allocation concealment was strictly implemented to prevent selection bias. The randomization sequence was stored in a password-protected electronic file, and investigators enrolling participants had no prior access to assignment details, Blinding description: The participants, investigator, and healthcare providers (doctors and nurses) were blinded. Blinding was achieved by placing the drug (Eltrombopag Olamine) and the placebo in identical white capsules. The medications were prepared by a pharmacist in a separate room that was inaccessible to everyone else. The white capsules, labeled with patient IDs, were provided to the healthcare providers, who administered the medications to the patients according to the labeled IDs, thereby ensuring adherence to the blinding protocol. 2-3 Dengue Fever. Intervention 1: Intervention group: Tab Eltrombopag Olamine 25 mg will be given orally for 3 days once a day alongwith routine medical care. Intervention 2: Control group: Oral Glucose tablets will be given for 3 days once daily alongwith routine medical care as a placebo drug. Yes - There is a plan to make this available What will be shared: The Deidentified Individual Participant Data Set, Study Protocol, Statistical Analysis Plan, and Informed Consent forms will be made available to desirous researchers upon reasonable requests, and after clearance from the institutional data registry body. The said documents will be shared in a non-editable format via email after scrutinizing the need for subject documents by the requesting authorities When: The data will be available 6 months after the publication of the trial. To whom: The data will be available to researchers and teaching institutes for literary and educational purposes, Conditions: The data will be available for academic, research and literary purposes. Tt will not be available for commercial use. Where to obtain: The data can be obtained via Email from: Dr Fatima Masud Department of Medicine, Pak Emirates Military Hospital Rawalpindi fatimamasud454@gmail.com How to obtain: Data will be made available on reasonable request, after approval from the data registry department of the institute. Comments: